Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
Vol. 13, No. 12, 2014, pp. 2115-2118
Bioline Code: pr14292
Full paper language: English
Document type: Research Article
Document available free of charge
Tropical Journal of Pharmaceutical Research, Vol. 13, No. 12, 2014, pp. 2115-2118
© Copyright 2014 - Tropical Journal of Pharmaceutical Research
Safety of Oral Clemastine – Analysis of Data from Spontaneous Reporting System in Poland|
Han, Stanisław; Karłowicz-Bodalska, Katarzyna; Miśkiewicz, Katarzyna; Kutycka, Elżbieta & Kuchar, Ernest
Purpose: To analyse the safety of oral clemastine marketed in Poland based on spontaneous adverse
event reporting system.
Methods: We analyzed sales volume and data obtained from the monitoring of spontaneous reports on
the adverse effects of Clemastinum Hasco tablets (1.0 mg) and Clemastinum Hasco syrup (0.1 mg/mL)
received by the manufacturer (PPF HASCO-LEK S.A. Wroclaw, Poland) and National Monitoring Centre
in Warsaw in the period January 2007 to June 2012. The Polish system is mainly based on written
reports voluntarily submitted by healthcare professionals.
Results: A total of 2,089,717 units of Clemastinum Hasco tablets 1.0 mg and 1,965,340 units of
Clemastinum Hasco syrup 0.1 mg/mL were marketed during the period analyzed. Only one
spontaneous report on clemastine was registered in the period analyzed.
Conclusion: Oral clemastine is a safe medication, rarely causing adverse effects; Nevertheless, the
existing spontaneous monitoring system for adverse effects in Poland may not be sensitive enough and
therefore, needs improvement.
Clemastine; Adverse drug reactions; Pharmoepidemiology; Drug safety; Pharmacovigilance; Reporting system
Alternative site location: http://www.tjpr.org